JP2022518507A5 - - Google Patents

Info

Publication number
JP2022518507A5
JP2022518507A5 JP2021542397A JP2021542397A JP2022518507A5 JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5 JP 2021542397 A JP2021542397 A JP 2021542397A JP 2021542397 A JP2021542397 A JP 2021542397A JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5
Authority
JP
Japan
Prior art keywords
antibody
treatment
composition according
day
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542397A
Other languages
English (en)
Japanese (ja)
Other versions
JP7511566B2 (ja
JP2022518507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014998 external-priority patent/WO2020154626A1/en
Publication of JP2022518507A publication Critical patent/JP2022518507A/ja
Publication of JP2022518507A5 publication Critical patent/JP2022518507A5/ja
Priority to JP2024102181A priority Critical patent/JP7823117B2/ja
Application granted granted Critical
Publication of JP7511566B2 publication Critical patent/JP7511566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542397A 2019-01-25 2020-01-24 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与 Active JP7511566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102181A JP7823117B2 (ja) 2019-01-25 2024-06-25 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796953P 2019-01-25 2019-01-25
US62/796,953 2019-01-25
PCT/US2020/014998 WO2020154626A1 (en) 2019-01-25 2020-01-24 Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102181A Division JP7823117B2 (ja) 2019-01-25 2024-06-25 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与

Publications (3)

Publication Number Publication Date
JP2022518507A JP2022518507A (ja) 2022-03-15
JP2022518507A5 true JP2022518507A5 (cg-RX-API-DMAC7.html) 2023-11-27
JP7511566B2 JP7511566B2 (ja) 2024-07-05

Family

ID=69740563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542397A Active JP7511566B2 (ja) 2019-01-25 2020-01-24 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与
JP2024102181A Active JP7823117B2 (ja) 2019-01-25 2024-06-25 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102181A Active JP7823117B2 (ja) 2019-01-25 2024-06-25 非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量及び投与

Country Status (18)

Country Link
US (1) US20220235121A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914617B1 (cg-RX-API-DMAC7.html)
JP (2) JP7511566B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250016490A (cg-RX-API-DMAC7.html)
CN (2) CN113614105A (cg-RX-API-DMAC7.html)
AU (3) AU2020213121A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014472A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127797A1 (cg-RX-API-DMAC7.html)
DK (1) DK3914617T3 (cg-RX-API-DMAC7.html)
ES (1) ES2980453T3 (cg-RX-API-DMAC7.html)
FI (1) FI3914617T3 (cg-RX-API-DMAC7.html)
HU (1) HUE067202T2 (cg-RX-API-DMAC7.html)
LT (1) LT3914617T (cg-RX-API-DMAC7.html)
MX (1) MX2021008919A (cg-RX-API-DMAC7.html)
PL (1) PL3914617T3 (cg-RX-API-DMAC7.html)
PT (1) PT3914617T (cg-RX-API-DMAC7.html)
SI (1) SI3914617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020154626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗c5抗体の産生方法
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下(sc)施用抗c5抗体治疗补体相关病症
CA3173016A1 (en) * 2021-01-22 2022-07-28 Gin-Fu CHEN Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
WO2022234541A1 (en) * 2021-05-07 2022-11-10 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
JP5878270B2 (ja) 2012-12-19 2016-03-08 プロメラス, エルエルシー 高純度ノルボルネンアルカノールおよびその誘導体の製造方法
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
US20190023775A1 (en) * 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
ES2965486T3 (es) * 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients

Similar Documents

Publication Publication Date Title
FI3914617T3 (fi) Anti-c5-vasta-aineiden annostus ja antaminen epätyypillisen hemolyyttis-ureemisen oireyhtymän (ahus) hoitoon
Teixeira et al. Continuous kidney replacement therapies: core curriculum 2025
JP2020176155A5 (cg-RX-API-DMAC7.html)
US20150080849A1 (en) Multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit
RU2013149792A (ru) Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
JP2021526534A5 (cg-RX-API-DMAC7.html)
Hayes et al. Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report
JP2023533030A5 (cg-RX-API-DMAC7.html)
Allan et al. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy
Nakamura et al. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis
Lippi et al. Double filtration plasmapheresis in a dog with multiple myeloma and hyperviscosity syndrome
Lamy et al. Comparison between on-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal
Vaaraa et al. Renal Replacement Therapy
Caruana et al. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis
JP2023526590A5 (cg-RX-API-DMAC7.html)
Vos et al. Drug clearance by continuous haemodiafiltration: results with the AN-69 capillary haemofilter and recommended dose adjustments for seven antibiotics
Agreda‐Vásquez et al. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective
Ptak et al. Immunoadsorption therapy and complement activation
Marshall Current status of dosing and quantification of acute renal replacement therapy. Part 1: Mechanisms and consequences of therapy under‐delivery
WO2022171732A1 (en) Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
Leitman et al. Homozygous familial hypercholesterolemia. Selective removal of low‐density lipoproteins by secondary membrane filtration
JP2023507852A5 (cg-RX-API-DMAC7.html)
Shah et al. Rapid removal of vancomycin by continuous veno-venous hemofiltration
Miyakawa et al. Dialysis
US9861685B2 (en) Methods of treating hemoglobinopathies